CAS number and identifiers (chemical data)

• CAS number: 195875-84-4. PubChem+1

• PubChem CID: 11370864. PubChem

• Other names / synonyms: Tesofensine, NS-2330. PubChem

(These identifiers are stable chemical registry entries and useful when searching chemical catalogs, safety data sheets, or regulatory databases.) PubChem

How Tesofensine works — technical breakdown (mechanism of action)

• Pharmacological class: Tesofensine is a monoamine reuptake inhibitor (MRI) that blocks presynaptic transporters for the three major monoamines: dopamine (DA), norepinephrine (NE), and serotonin (5-HT). This increases the availability of these neurotransmitters at synapses and in brain regions that regulate appetite and energy balance. PubMed+1

• Central effects relevant to weight regulation: By increasing NE and 5-HT signaling in hypothalamic and other brain circuits, tesofensine appears to reduce appetite and food intake and may also increase resting energy expenditure via sympathetic activation in preclinical and clinical studies. PubMed+1

• Pharmacokinetics (summary): Reported oral bioavailability is high; elimination half-life is long (reported in published sources). Metabolism involves hepatic pathways. (See product/compound summaries for full PK detail). PubChem

How Tesofensine works — plain language

• Tesofensine raises brain levels of three “messenger” chemicals — dopamine, norepinephrine and serotonin.

• Those chemicals help regulate hunger, motivation, and how the body uses energy.

• In controlled clinical trials, people taking tesofensine ate less and lost more weight than those on placebo, under the trial conditions. PubMed

Selected clinical evidence (high-priority studies)

• Phase II randomized trial (Astrup et al., Lancet 2008) — In a 24-week, randomized, double-blind, placebo-controlled study in obese patients, tesofensine produced dose-dependent weight loss substantially greater than placebo under study conditions; authors called for further phase-III evaluation. PubMed

• Reviews and evaluations — Several reviews and commentary papers summarize the efficacy signals and safety considerations (e.g., potential increases in heart rate and blood pressure observed in some trial participants). PubMed+1

• Preclinical / mechanistic research — Animal and cellular studies further examine neural circuit actions (e.g., hypothalamic ensembles, effects on feeding circuits) and metabolic effects on energy expenditure. PLOS